Remsleep Holdings INC
Market Movers (8-K)
OTC.Pink
RemSleep Holdings, Inc. has undergone a significant shift in control and leadership, with new officers appointed and a change in majority ownership of preferred shares.
Delay expected
OTC.Pink
REMSleep Holdings appoints Jeffrey Marshall as CEO and reconstitutes its board following the passing of founder Thomas Wood, outlining new leadership's compensation and financial controls.
Worse than expected
Capital raise
OTC.Pink
REMSleep Holdings, Inc. has announced it has received 510(k) clearance from the FDA for its new Deltawave CPAP Pillows Interface mask.
Quarterly Earnings (10-Q)
OTC.Pink
REMSLEEP Holdings, Inc. reported a significantly wider net loss in Q3 2025, driven by a sharp decline in revenue during its product transition and substantial non-cash compensation expenses.
Capital raise
Worse than expected
OTC.Pink
REMSLEEP Holdings, Inc. reports a significant revenue decline and increased liabilities, raising substantial doubt about its ability to continue as a going concern despite new product sales.
Worse than expected
Capital raise
OTC.Pink
Remsleep Holdings reports a net loss of $85,488 for Q1 2025, shifting focus to the launch of their DeltaWave product while navigating going concern challenges.
Worse than expected
Capital raise
OTC.Pink
REMSleep Holdings reported a net loss of $756,088 for the nine months ended September 30, 2024, with increased development expenses and concerns about the company's ability to continue as a going concern.
Worse than expected
Capital raise
OTC.Pink
REMSleep Holdings experienced a decrease in revenue and increased net loss in the second quarter of 2024, while also achieving FDA approval for its DeltaWave product.
Worse than expected
Capital raise
OTC.Pink
REMSleep Holdings has filed an amended 10-Q report for the quarter ended March 31, 2024, to correct the number of outstanding shares, while also reporting a net loss and ongoing concerns about its ability to continue as a going concern.
Worse than expected
Delay expected
Capital raise
Annual Reports (10-K)
OTC.Pink
REMSleep Holdings reports a significant net loss for 2025 while transitioning to its new DeltaWave CPAP product line.
Worse than expected
Capital raise
OTC.Pink
REMSleep Holdings, Inc. reports a net loss for 2024 but recognizes revenue from ResPlus CPAP system sales and continues development of its DeltaWave product.
Capital raise
Worse than expected
OTC.Pink
REMSleep Holdings reports a net loss of $1.78 million for 2023 and acknowledges substantial doubt about its ability to continue as a going concern.
Worse than expected
Delay expected
Capital raise
New Public Companies (S-1)
OTC.Pink
RemSleep Holdings seeks to register 300 million shares for resale by Quick Capital, aiming to raise up to $2.9 million.
Capital raise
Worse than expected